Table 1. Description of included trials.

Study	Size (n)	Follow-up (weeks)	Age		Sex: F/M (n)		Baseline PC ´109/L		Duration of ITP (years)		Splenectomy (Y/N)		Outcomes
			TPO-RA	Control	TPO-RA	Control	TPO-RA	Control	TPO-RA	Control	TPO-RA	Control
Tarantino et al. 2016	62	25	10 (6–14)	7.5 (6.5–13.5)	24/18	11/9	17·8 (7·5–24·5)	17·7 (9·8–24·1)	1.9 (1.0–4.2)	2.2 (1.5–3.7)	1/41	1/19	OR; DR; Rescue medication; Any bleeding events; Severe bleeding events; Severe AEs
Mathias et al. 2016	62	25	9.7 ± 4.1	9.4 ± 4.7	24/18	11/9	19.9 ± 19.3	17.5 ± 10.7	3.0 ± 2.8	3.0 ± 2.3	1/41	1/19	HqoL; Parental burden
Klaassen et al. 2012	22	13	9 (1–17)	11 (2–14)	4/13	2/3	13 (2–27)	9 (8–29)	2.4 (0.8–14.0)	4.1 (0.6–8.6)	6/11	2/3	HqoL; Parental burden
Elalfy et al. 2011	18	12	9.5 (2.5–16)	7 (4–15)	2/10	3/3	10.5(2–20)	10.5(6–20)	2.3 (1.2–7.0)	3.0 (1.5–6.5)	0/12	0/6	OR; Rescue medication; Severe bleeding events; All AEs; Severe AEs;
Bussel et al. 2011	22	12	9 (1–17)	11 (2–14)	4/13	2/3	13 (2–27)	9 (8–29)	2.4 (0.8–14.0)	4.1 (0.6–8.6)	6/11	2/3	OR; DR; Rescue medication; Any bleeding events; Severe bleeding events; Cilinical bleeding events; All AEs; Severe AEs
Grainger et al. 2015	92	12	9.4 (8.2–10.5)	9.8 (8.3–11.3)	30/33	14/15	< 30	< 30	3.4 ± 2.8	4.4 ± 3.4	4/59	0/29	OR; DR; Rescue medication; Any bleeding events; Cilinical bleeding events; All AEs; Severe AEs
Bussel et al. 2015	67	7	9 (8–10)	10 (8–12)	27/18	13/9	< 30	< 30	> 0.5	> 0.5	5/40	0/22	OR; DR; Rescue medication; Any bleeding events; Severe bleeding events; Cilinical bleeding events; All AEs; Severe AEs

F/M: female/male; PC: platelet count; ITP: immune thrombocytopenia; Y/N: yes/no; OR: overall platelet response; DR: durable response; HqoL: health-related quality of life; AEs: adverse events.